We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

L-Arginine Supplementation and Exercise; L-Arginine Supplementation and Renal Function

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00213915
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : November 29, 2007
Information provided by:
University Hospital, Strasbourg, France

September 13, 2005
September 21, 2005
November 29, 2007
February 2004
Not Provided
Maximal and sub maximal exercise capacity at the end of the 6 weeks L-arginine supplementation. Renal function at the end of the 6 weeks
Same as current
Complete list of historical versions of study NCT00213915 on ClinicalTrials.gov Archive Site
No secondary effects
Same as current
Not Provided
Not Provided
L-Arginine Supplementation and Exercise; L-Arginine Supplementation and Renal Function
Effects of Oral Chronic L-Arginine Supplementation on Exercise and Renal Function of Heart Transplant Recipients
  • exercise capacities are still altered after heart transplantation partly due to peripheral endothelial dysfunction
  • cyclosporin-induced renal dysfunction may be due to renal endothelial dysfunction and can be reversed in an animal model by L-arginine supplementation
  • to determine the potential beneficial effect of L-arginine supplementation on exercise capacity and renal function of heart transplant recipients
Not Provided
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Heart Transplantation
Drug: 12 g of L-arginine glutamate during 6 weeks twice a day
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2004
Not Provided

Inclusion Criteria:

  • Male (> 18 years old) stable heart transplant recipient for at least 6 weeks
  • Stable treatment for at least 3 months
  • Sedentary people

Exclusion Criteria:

  • Unstable cardiac pathology
  • Obesity (IMC > 40)
  • Participation in another study in the last month
  • Chronic renal failure (creatinine clearance < 20 ml/min)
  • Renal transplantation
  • Diabetes
  • Impossibility to practice exercise test
  • Nitrate therapy
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
University Hospital, Strasbourg, France
Not Provided
Principal Investigator: Stephane DOUTRELEAU, MD Service de Physiologie et d'Explorations Fonctionnelles
University Hospital, Strasbourg, France
November 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP